RedHill Biopharma Ltd. (RDHL)
Develops medicines treating stomach infections, travelers' diarrhea, and COVID-19.
$0.73+0.04%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-39.2%
The outlook
RDHL is trading near its 52-week lows, well below both its 50- and 200-day moving averages. The stock shows minimal momentum today and limited upside within its annual range. Analyst coverage appears thin for this biotech company.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Market cap
$4.4M
52-wk high
$2.79
52-wk low
$0.63
50-day avg
$0.85
200-day avg
$1.05
Trailing P/E
—